NLS Pharmaceutics AG
NASDAQ:NLSP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NLS Pharmaceutics AG
Common Stock
NLS Pharmaceutics AG
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Common Stock
$2.9m
|
CAGR 3-Years
104%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Common Stock
$766m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Roche Holding AG
SIX:ROG
|
Common Stock
CHf107m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Common Stock
CHf587k
|
CAGR 3-Years
20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Common Stock
$25m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
NLS Pharmaceutics AG
Glance View
NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder. The company is headquartered in Stans, Nidwalden and currently employs 6 full-time employees. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
See Also
What is NLS Pharmaceutics AG's Common Stock?
Common Stock
2.9m
USD
Based on the financial report for Dec 31, 2024, NLS Pharmaceutics AG's Common Stock amounts to 2.9m USD.
What is NLS Pharmaceutics AG's Common Stock growth rate?
Common Stock CAGR 5Y
81%
Over the last year, the Common Stock growth was 296%. The average annual Common Stock growth rates for NLS Pharmaceutics AG have been 104% over the past three years , 81% over the past five years .
